Gäckler, Anja
Dolff, Sebastian
Rohn, Hana
Korth, Johannes
Wilde, Benjamin
Eisenberger, Ute
Mitchell, Anna
Kribben, Andreas
Witzke, Oliver
Funding for this research was provided by:
TEVA Pharmaceuticals BV
Article History
Received: 18 March 2018
Accepted: 17 April 2019
First Online: 14 May 2019
Ethics approval and consent to participate
: This study was conducted in compliance with Good Clinical Practices (GCP) and the Declaration of Helsinki, and in accordance with applicable legal and regulatory requirements. All patients gave informed consent. The study protocol was approved by the ethics commission of the medical faculty of the University Duisburg-Essen (10–4300) and registered in the European Union Clinical Trials Register (EudraCT No. 2009–011354-18).
: Not applicable.
: AG received travel grants, speaker’s fees and research support from Amgen, Amicus, Alexion, Astellas and Astute. SD received travel grants and/or honoraria from Astellas, Novartis and Roche. HG received travel grants from Astellas, Chiesi and Novartis. JK received travel grants from Astellas, Novartis and Roche. BW has received travel grants from Alexion, Astellas, Biohope, Chiesi, Chemocentryx, Cytosorbents, Novartis, Pfizer, Roche, Sanofi, Teva and Wyeth. UE received research support and/or honoraria from Astellas, Astute, Amgen, Novartis and Teva. AM reports no conflicts of interest. AK received honoraria from Novartis. OW received research funds and/or honoraria from Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Janssen-Cilag, MSD, Novartis, Pfizer, Roche and Shire.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.